Skip to main content

Voyager Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

VYGR$1.99+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

​​​​
Date: February 28, 2024VOYAGER THERAPEUTICS, INC.
By:/s/ Alfred Sandrock, M.D., Ph.D.
​​​Alfred Sandrock, M.D., Ph.D.Chief Executive Officer, President, and Director

SIGNATURES AND POWER OF ATTORNEY** **

We, the undersigned directors and officers of Voyager Therapeutics, Inc. (the “Company”), hereby severally constitute and appoint Alfred Sandrock and Peter Pfreundschuh, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to therequirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.

NameTitleDate
​​​​​
/s/Alfred Sandrock, M.D., Ph.D.​Chief Executive Officer, President, and Director​February 28, 2024
Alfred Sandrock, M.D., Ph.D.​(Principal Executive Officer)​
​​​​​
/s/Peter P. Pfreundschuh​Chief Financial Officer​February 28, 2024
Peter P. Pfreundschuh​(Principal Financial and Accounting Officer)​
​​​​​
/s/Michael Higgins​Director (Chairman of the Board)​February 28, 2024
Michael Higgins​​
​​​​​
/s/Grace E. Colón, Ph.D.​Director​February 28, 2024
Grace E. Colón, Ph.D.​​
​​​​​
/s/Jim Geraghty​Director​February 28, 2024
Jim Geraghty​​
​​​​​
/s/Steven Hyman, M.D.​Director​February 28, 2024
Steven Hyman, M.D.​​​
​​​​​
/s/Catherine J. Mackey, Ph.D.​Director​February 28, 2024
Catherine J. Mackey, Ph.D.​​​
​​​​​
/s/Jude Onyia, Ph.D.​Director​February 28, 2024
Jude Onyia, Ph.D.​​​
​​​​​
/s/Glenn Pierce, M.D., Ph.D.​Director​February 28, 2024
Glenn Pierce, M.D., Ph.D.​​​
​​​​​
/s/George Scangos, Ph.D.​Director​February 28, 2024
George Scangos, Ph.D.​​​
​​​​​
/s/Nancy Vitale​Director​February 28, 2024
Nancy Vitale​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.